期刊
BIOMEDICINES
卷 10, 期 10, 页码 -出版社
MDPI
DOI: 10.3390/biomedicines10102387
关键词
psoriatic diseases; psoriatic arthritis; psoriasis; multi-omics; data integration
资金
- Innovative Medicines Initiative 2 Joint Undertaking (JU) [101007757]
- European Union
- EFPIA
The definitive diagnosis and early treatment of immune-mediated inflammatory diseases (IMIDs) are challenging due to variable clinical manifestations. Psoriatic arthritis (PsA) is an example of such a disease. The detection of molecular biomarkers offers hope for the early diagnosis and treatment of PsA, but specific biomarkers are not yet available. By analyzing multi-omics data and integrating them with clinical assessment, it is possible to develop molecular profiles that improve the diagnosis and treatment outcomes of PsA patients.
The definitive diagnosis and early treatment of many immune-mediated inflammatory diseases (IMIDs) is hindered by variable and overlapping clinical manifestations. Psoriatic arthritis (PsA), which develops in similar to 30% of people with psoriasis, is a key example. This mixed-pattern IMID is apparent in entheseal and synovial musculoskeletal structures, but a definitive diagnosis often can only be made by clinical experts or when an extensive progressive disease state is apparent. As with other IMIDs, the detection of multimodal molecular biomarkers offers some hope for the early diagnosis of PsA and the initiation of effective management and treatment strategies. However, specific biomarkers are not yet available for PsA. The assessment of new markers by genomic and epigenomic profiling, or the analysis of blood and synovial fluid/tissue samples using proteomics, metabolomics and lipidomics, provides hope that complex molecular biomarker profiles could be developed to diagnose PsA. Importantly, the integration of these markers with high-throughput histology, imaging and standardized clinical assessment data provides an important opportunity to develop molecular profiles that could improve the diagnosis of PsA, predict its occurrence in cohorts of individuals with psoriasis, differentiate PsA from other IMIDs, and improve therapeutic responses. In this review, we consider the technologies that are currently deployed in the EU IMI2 project HIPPOCRATES to define biomarker profiles specific for PsA and discuss the advantages of combining multi-omics data to improve the outcome of PsA patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据